Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Updates on the Management of Thyroid Cancer.

Literature DB >> 32040962

Updates on the Management of Thyroid Cancer.

Katherine A Araque¹, Sriram Gubbi², Joanna Klubo-Gwiezdzinska².

Abstract

The diagnostic modalities, stratification tools, and treatment options for patients with thyroid cancer have rapidly evolved since the development of the American Thyroid Association (ATA) guidelines in 2015. This review compiles newer concepts in diagnosis, stratification tools and treatment options for patients with differentiated thyroid cancer (DTC), medullary thyroid carcinoma (MTC) and anaplastic thyroid cancer (ATC). Newer developments apply precision medicine in thyroid cancer patients to avoid over-treatment in low risk disease and under-treatment in high risk disease. Among novel patient-tailored therapies are selective RET inhibitors that have shown efficacy in the treatment of MTC with limited systemic toxicity compared with non-specific tyrosine kinase inhibitors. The combination of BRAF and MEK inhibitors have revolutionized management of BRAF V600E mutant ATC. Several immunotherapeutic agents are being actively investigated in the treatment of all forms of thyroid cancer. In this review, we describe the recent advances in the diagnosis and management of DTC, MTC, and ATC, with an emphasis on novel treatment modalities. © Georg Thieme Verlag KG Stuttgart · New York.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2020 PMID： 32040962 PMCID： PMC7415555 DOI： 10.1055/a-1089-7870

Source DB: PubMed Journal: Horm Metab Res ISSN： 0018-5043 Impact factor: 2.936

99 in total

1. Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: A name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment.

Authors: Lester Dr Thompson
Journal: Mod Pathol Date: 2016-04-22 Impact factor: 7.842

Review 2. Conservative Surveillance Management of Low-Risk Papillary Thyroid Microcarcinoma.

Authors: Akira Miyauchi; Yasuhiro Ito
Journal: Endocrinol Metab Clin North Am Date: 2018-12-23 Impact factor: 4.741

3. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.

Authors: Gilbert J Cote; Caitlin Evers; Mimi I Hu; Elizabeth G Grubbs; Michelle D Williams; Tao Hai; Dzifa Y Duose; Michal R Houston; Jacquelin H Bui; Meenakshi Mehrotra; Steven G Waguespack; Naifa L Busaidy; Maria E Cabanillas; Mouhammed Amir Habra; Rajyalakshmi Luthra; Steven I Sherman
Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958

Review 4. Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer.

Authors: R Michael Tuttle; Marcia S Brose; Enrique Grande; Sun Wook Kim; Makoto Tahara; Mona M Sabra
Journal: Best Pract Res Clin Endocrinol Metab Date: 2017-05-12 Impact factor: 4.690

5. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2).

Authors: Livia Lamartina; Giorgio Grani; Emanuela Arvat; Alice Nervo; Maria Chiara Zatelli; Roberta Rossi; Efisio Puxeddu; Silvia Morelli; Massimo Torlontano; Michela Massa; Rocco Bellantone; Alfredo Pontecorvi; Teresa Montesano; Loredana Pagano; Lorenzo Daniele; Laura Fugazzola; Graziano Ceresini; Rocco Bruno; Ruth Rossetto; Salvatore Tumino; Marco Centanni; Domenico Meringolo; Maria Grazia Castagna; Domenico Salvatore; Antonio Nicolucci; Giuseppe Lucisano; Sebastiano Filetti; Cosimo Durante
Journal: Endocr Relat Cancer Date: 2017-11-30 Impact factor: 5.678

6. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors.

Authors: Electron Kebebew; Francis S Greenspan; Orlo H Clark; Kenneth A Woeber; Alex McMillan
Journal: Cancer Date: 2005-04-01 Impact factor: 6.860

7. A phase II study of gefitinib in patients with advanced thyroid cancer.

Authors: Nathan A Pennell; Gilbert H Daniels; Robert I Haddad; Douglas S Ross; Tracey Evans; Lori J Wirth; Panos H Fidias; Jennifer S Temel; Sarada Gurubhagavatula; Rebecca Suk Heist; John R Clark; Thomas J Lynch
Journal: Thyroid Date: 2008-03 Impact factor: 6.568

8. Patient Experience of Thyroid Cancer Active Surveillance in Japan.

Authors: Louise Davies; Benjamin R Roman; Mitsuhiro Fukushima; Yasuhiro Ito; Akira Miyauchi
Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-04-01 Impact factor: 6.223

9. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Authors: Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov
Journal: J Clin Endocrinol Metab Date: 2003-05 Impact factor: 5.958

Review 10. Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy.

Authors: Maria E Cabanillas; Mark Zafereo; G Brandon Gunn; Renata Ferrarotto
Journal: J Oncol Pract Date: 2016-06 Impact factor: 3.840

26 in total

1. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.

Authors: Jinyan Chai; Ruiguo Zhang; Wei Zheng; Guizhi Zhang; Qiang Jia; Jian Tan; Zhaowei Meng; Renfei Wang
Journal: Front Endocrinol (Lausanne) Date: 2022-06-28 Impact factor: 6.055

Review 2. Peptide Receptor Radionuclide Therapy in Thyroid Cancer.

Authors: Sriram Gubbi; Christian A Koch; Joanna Klubo-Gwiezdzinska
Journal: Front Endocrinol (Lausanne) Date: 2022-05-30 Impact factor: 6.055

3. Roles of Cadherin2 in Thyroid Cancer.

Authors: Yun Chen; Chaojin Hong; Qihao Zhou; Zhiquan Qin
Journal: Front Oncol Date: 2022-06-09 Impact factor: 5.738

Review 4. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.

Authors: Lori J Wirth; Cosimo Durante; Duncan J Topliss; Eric Winquist; Eyal Robenshtok; Hiroyuki Iwasaki; Markus Luster; Rossella Elisei; Sophie Leboulleux; Makoto Tahara
Journal: Oncologist Date: 2022-07-05 Impact factor: 5.837

5. Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review.

Authors: Jingxin Mao; Xingliang Huang; Mohammad K Okla; Mostafa A Abdel-Maksoud; Ayman Mubarak; Zahid Hameed; Razia Noreen; Aqsa Chaudhary; Shakira Ghazanfar; Yixuan Liao; Yasir Hameed; Chen Li
Journal: Comput Math Methods Med Date: 2022-04-30 Impact factor: 2.809

6. Development and validation of a prognostic nomogram to predict overall survival and cancer-specific survival for patients with anaplastic thyroid carcinoma.

Authors: Weiwei Gui; Weifen Zhu; Weina Lu; Chengxin Shang; Fenping Zheng; Xihua Lin; Hong Li
Journal: PeerJ Date: 2020-05-21 Impact factor: 2.984

7. Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience.

Authors: Lucia Brilli; Cristina Dalmiglio; Tania Pilli; Filomena Barbato; Fabio Maino; Marco Capezzone; Alessandra Cartocci; Maria Grazia Castagna
Journal: J Clin Med Date: 2021-01-20 Impact factor: 4.241